Prostatic Neoplasms, Castration-Resistant Clinical Trial
— LACOG 1818Official title:
Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.
Verified date | March 2024 |
Source | Latin American Cooperative Oncology Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Survival outcomes in metastatic prostate cancer in the population Brazilian - analysis of individual characteristics and modalities of treatment in different national health institutions
Status | Active, not recruiting |
Enrollment | 584 |
Est. completion date | July 1, 2024 |
Est. primary completion date | July 1, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017. Exclusion Criteria: - Diagnosis of localized or locally advanced or metastatic disease sensitive to castration; - Patients with medical records filled with incomplete data that make it impossible to evaluate the treatment received. |
Country | Name | City | State |
---|---|---|---|
Brazil | CPO Pucrs | Porto Alegre | RS |
Brazil | Centro de Estudos e Pesquisas de Hematologia e Oncologia - CEPHO | Santo André | São Paulo |
Brazil | A.C.Camargo Cancer Center | São Paulo | |
Brazil | BP - A Beneficência Portuguesa de São Paulo | São Paulo | |
Brazil | Centro Paulista de Oncologia | São Paulo | SP |
Brazil | Hospital Santa Marcelina | São Paulo | |
Brazil | Irmandade da Santa Casa de Misericórdia de São Paulo - Hospital Central | São Paulo | |
Brazil | Sírio Libanês | São Paulo | SP |
Lead Sponsor | Collaborator |
---|---|
Latin American Cooperative Oncology Group |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Describe cause-specific survival in patients with castration-resistant prostate cancer in different institutions in Brazil. | December of 2017 | ||
Secondary | To describe the sociodemographic characteristics of patients with castration-resistant metastatic prostate cancer in Brazil; | December of 2017 | ||
Secondary | To describe comorbidities of patients with castration-resistant metastatic prostate cancer in Brazil; | December of 2017 | ||
Secondary | To describe the clinicopathological characteristics of patients with metastatic castration-resistant prostate cancer in Brazil; | December of 2017 | ||
Secondary | To compare overall survival among patients with castration-resistant metastatic prostate cancer treated in the SUS and in the private network; | December of 2017 | ||
Secondary | To compare the treatments performed by patients with castration-resistant metastatic prostate cancer in the SUS and in the private network; | December of 2017 | ||
Secondary | To describe the rates of skeletal-related complications | December of 2017 | ||
Secondary | To describe the rate of admissions | December of 2017 | ||
Secondary | To describe the number of lines of treatment that patients have undergone | December of 2017 | ||
Secondary | To describe the presence or absence of treatments bone-directed | December of 2017 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03325127 -
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
|
||
Withdrawn |
NCT02906605 -
A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05743621 -
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1 | |
Completed |
NCT02204072 -
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
|
Phase 1 | |
Recruiting |
NCT05393791 -
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
|
Phase 2 | |
Active, not recruiting |
NCT03927391 -
Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects
|
Phase 4 | |
Completed |
NCT02450812 -
Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
|
||
Not yet recruiting |
NCT06353386 -
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03431350 -
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03822845 -
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT02162836 -
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1 | |
Completed |
NCT02899104 -
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
|
||
Active, not recruiting |
NCT04381832 -
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03563014 -
A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
|
||
Active, not recruiting |
NCT05968599 -
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
|
||
Active, not recruiting |
NCT02803437 -
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
|
||
Recruiting |
NCT05944237 -
HTL0039732 in Participants With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03173859 -
Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients
|
Phase 2 | |
Terminated |
NCT02057666 -
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
|
Phase 3 |